Globus Medical, Inc. $GMED Shares Purchased by Inspire Investing LLC

Key Points

• Inspire Investing increased its Globus Medical stake by 464.8% in the third quarter, bringing its holdings to 41,600 shares valued at approximately $3.1 million. Institutional investors collectively own 95.16% of GMED.
• Analysts maintain a generally positive outlook, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $99.46. Recent targets range from $82 to $100.
• Globus Medical exceeded quarterly expectations, reporting EPS of $1.34 versus the $1.10 consensus estimate and revenue of $789.61 million, up 5.9% year over year. However, two directors recently sold a combined 55,000 shares.

Inspire Investing LLC raised its stake in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 464.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,600 shares of the medical device company's stock after buying an additional 34,234 shares during the period. Inspire Investing LLC's holdings in Globus Medical were worth $3,116,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Paradigm Capital Management Inc. NY acquired a new stake in shares of Globus Medical during the 2nd quarter valued at about $70,042,000. American Capital Management Inc. bought a new stake in shares of Globus Medical during the 2nd quarter worth about $51,599,000. Hawk Ridge Capital Management LP bought a new position in shares of Globus Medical in the 1st quarter valued at approximately $43,078,000. Arrowstreet Capital Limited Partnership boosted its position in Globus Medical by 107.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company's stock worth $78,656,000 after purchasing an additional 471,875 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company's stock valued at $656,831,000 after purchasing an additional 328,217 shares during the period. Institutional investors and hedge funds own 95.16% of the company's stock.

Analysts Set New Price Targets

GMED has been the topic of a number of recent analyst reports. BMO Capital Markets initiated coverage on Globus Medical in a research note on Wednesday, July 8th. They issued an "outperform" rating and a $94.00 price objective on the stock. UBS Group started coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a "neutral" rating and a $82.00 price objective for the company. Truist Financial lowered their price target on Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Thursday, July 16th. Wells Fargo & Company lowered their price objective on Globus Medical from $103.00 to $99.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of Globus Medical in a report on Friday, October 9th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $99.46.

Insider Buying and Selling at Globus Medical

In related news, Director Stephen Zarrilli sold 25,000 shares of the firm's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director owned 25,000 shares of the company's stock, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director James R. Tobin sold 30,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the sale, the director owned 15,000 shares of the company's stock, valued at $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 18.38% of the company's stock.

Globus Medical Price Performance

GMED stock opened at $81.47 on Friday. The company has a 50 day moving average price of $78.03 and a 200 day moving average price of $81.19. Globus Medical, Inc. has a fifty-two week low of $59.51 and a fifty-two week high of $101.40. The stock has a market capitalization of $10.94 billion, a PE ratio of 20.84, a price-to-earnings-growth ratio of 1.31 and a beta of 0.96.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. During the same quarter in the prior year, the firm posted $0.86 earnings per share. The firm's revenue for the quarter was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, equities analysts expect that Globus Medical, Inc. will post 4.99 earnings per share for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.